The investigators found evidence that Foralumab dampened the inflammatory T cell response and minimised lung inflammation in Covid-19 patients. Credit: Tumisu from Pixabay.

Investigators from Brigham and Women’s Hospital (BWH) have tested the nasal administration of Foralumab, an anti-CD3 monoclonal antibody, as part of a pilot trial where the drug decreased inflammatory markers in Covid-19 patients.

BWH is a founding member of the Mass General Brigham healthcare system.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In this trial, the investigators found evidence that Foralumab dampened the inflammatory T cell response and minimised lung inflammation in Covid-19 patients.

Based on further analysis, the same gene expression modulation was observed in patients with multiple sclerosis, who experienced decreased brain inflammation.

This suggested that the drug could be used for the treatment of other diseases.

See Also:

BWH Ann Romney Center for Neurologic Diseases assistant scientist Thais Moreira said: “We discovered a way to shut down inflammation not only seen in Covid-19, but also in a patient with multiple sclerosis, as well as in healthy patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This is very exciting because not only does our study suggest that this new monoclonal antibody drug is safe and can modulate the immune system without major side effects, but it can also decrease inflammation in multiple realms, so it may be useful for treating other diseases.”

The immune system was found to be overactive in both Covid-19 and multiple sclerosis.

Manufactured by Tiziana Life Sciences, Foralumab stimulates the immune system’s regulatory T cells or anti-inflammatory cells to decrease inflammation.

The team is proceeding with a double-blind, placebo-controlled clinical trial in progressive multiple sclerosis and is also planning a new study for long Covid.

The Ann Romney Center for Neurological Diseases provided funding for the study.